6-Br-APB je sintetičko jedinjenje koje deluje kao selektivni agonist D1 receptora.[5] (R)-enantiomer je potentan pun agonist, dok (S) enantiomer ima D1 selektivnost, ali je slab parcijalni agonist.[6] (R)-6-Br-APB i slični D1-selektivni puni agonisti, kao što su SKF-81297 i SKF-82958 proizvode karakteristične anoreksične efekte, stereotipno ponašanje i samoadministraciju kod životinja. On ima sličan mada ne identičan profile sa dopaminergičkim stimulansima poput amfetamina.[7][8][9]
6-Br-APB
|
| (IUPAC) ime
|
| 3-alil-6-bromo-1-fenil-1,2,4,5-tetrahidro-3-benzazepin-7,8-diol
|
| Klinički podaci
|
| Identifikatori
|
| CAS broj
|
135974-57-1
|
| ATC kod
|
nije dodeljen
|
| PubChem[1][2]
|
11957483
|
| ChemSpider[3]
|
8627436
|
| ChEMBL[4]
|
CHEMBL34095  Y
|
| Hemijski podaci
|
| Formula
|
C19H20BrNO2
|
| Mol. masa
|
374,27 g/mol
|
| SMILES
|
eMolekuli & PubHem
|
| InChI |
|---|
InChI=1S/C19H20BrNO2/c1-2-9-21-10-8-14-15(11-17(22)19(23)18(14)20)16(12-21)13-6-4-3-5-7-13/h2-7,11,16,22-23H,1,8-10,12H2/t16-/m1/s1 Y
Key: KKZGFVAZUKHFAC-MRXNPFEDSA-N Y |
|
| Farmakoinformacioni podaci
|
| Trudnoća
|
?
|
| Pravni status
|
|
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
- ↑ Neumeyer JL, Baindur N, Niznik HB, Guan HC, Seeman P (December 1991). „(+/-)-3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepin, a new high-affinity D1 dopamine receptor ligand: synthesis and structure-activity relationship”. Journal of Medicinal Chemistry 34 (12): 3366–71. DOI:10.1021/jm00116a004. PMID 1684995.
- ↑ Neumeyer JL, Kula NS, Baldessarini RJ, Baindur N (April 1992). „Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue”. Journal of Medicinal Chemistry 35 (8): 1466–71. DOI:10.1021/jm00086a016. PMID 1533424.
- ↑ Rosenzweig-Lipson S, Hesterberg P, Bergman J (September 1994). „Observational studies of dopamine D1 and D2 agonists in squirrel monkeys”. Psychopharmacology 116 (1): 9–18. DOI:10.1007/BF02244865. PMID 7862937.
- ↑ Weed MR, Woolverton WL (December 1995). „The reinforcing effects of dopamine D1 receptor agonists in rhesus monkeys”. The Journal of Pharmacology and Experimental Therapeutics 275 (3): 1367–74. PMID 8531104.
- ↑ Barrett AC, Miller JR, Dohrmann JM, Caine SB (2004). „Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats”. Neuropharmacology 47 Suppl 1: 256–73. DOI:10.1016/j.neuropharm.2004.07.007. PMID 15464142.
